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Abstract
CCR5 is not only a coreceptor for HIV-1 infection in CD4+ T cells,
but also contributes to their functional fitness. Here, we show
that by limiting transcription of specific ceramide synthases,
CCR5 signaling reduces ceramide levels and thereby increases T-
cell antigen receptor (TCR) nanoclustering in antigen-experienced
mouse and human CD4+ T cells. This activity is CCR5-specific
and independent of CCR5 co-stimulatory activity. CCR5-deficient
mice showed reduced production of high-affinity class-switched
antibodies, but only after antigen rechallenge, which implies an
impaired memory CD4+ T-cell response. This study identifies a
CCR5 function in the generation of CD4+ T-cell memory
responses and establishes an antigen-independent mechanism
that regulates TCR nanoclustering by altering specific lipid
species.
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Introduction
The C-C motif chemokine receptor 5 (CCR5) is a seven-trans-
membrane G protein-coupled receptor (GPCR) expressed on the
surface of several innate and adaptive immune cell subtypes,
including effector and memory CD4+ T lymphocytes (Gonzalez-
Martin et al, 2012). CCR5 acts also a necessary coreceptor for
infection by HIV-1. An HIV-resistant population served to identify
a 32-bp deletion within the CCR5 coding region (ccr5D32), which
yields a non-functional receptor (Blanpain et al, 2002). Since
ccr5D32 homozygous individuals are seemingly healthy, a radical
body of thought considers that CCR5 is dispensable for immune
cell function.
Experimental and epidemiological evidence nonetheless indicates
that CCR5 has an important role in innate and acquired immune
responses. CCR5 and its ligands C-C motif ligand 3 (CCL3; also
termed macrophage inflammatory protein [MIP]-1a), CCL4 (MIP-
1b), CCL5 (regulated upon activation, normal T cell expressed and
secreted [RANTES]), and CCL3L1 have been associated with exacer-
bation of chronic inflammatory and autoimmune diseases. Despite
varying information due probably to ethnicity effects (Lee et al,
2013; Schauren et al, 2013), further complicated in admixed popula-
tions (Toson et al, 2017), epidemiological studies support the
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ccr5D32 allele as a marker for good prognosis for these overreactive
immune diseases (Vangelista & Vento, 2017). In contrast, ccr5D32
homozygotes are prone to fatal infections by several pathogens such
as influenza, West Nile, and tick-borne encephalitis viruses (Lim &
Murphy, 2011; Falcon et al, 2015; Ellwanger & Chies, 2019). The
mechanisms by which the ccr5D32 polymorphism affects all these
pathologies have usually been linked to the capacity of CCR5 to
regulate leukocyte trafficking. For example, CCR5 deficiency reduces
recruitment of influenza-specific memory CD8+ T cells and acceler-
ates macrophage accumulation in lung airways during virus rechal-
lenge (Dawson et al, 2000; Kohlmeier et al, 2008); this could lead to
acute severe pneumonitis, a fatal flu complication. CCR5 nonethe-
less has migration-independent functions that maximize T-cell acti-
vation by affecting immunological synapse (IS) formation (Molon
et al, 2005; Floto et al, 2006; Franciszkiewicz et al, 2009) as well as
T-cell transcription programs associated with cytokine production
(Lillard et al, 2001; Camargo et al, 2009). CCR5 and its ligands are
also critical for cell-mediated immunity to tumors and pathogens,
including HIV-1 (Dolan et al, 2007; Ugurel et al, 2008; Gonza´lez-
Martı´n et al, 2011; Bedognetti et al, 2013).
Whereas the role of CCR5 in T-cell priming is well established,
its involvement in memory responses has not been addressed in
depth. Only a single report suggested CCR5 involvement in CD4+
T-cell promotion of memory CD8+ T-cell generation through a
migration-dependent process (Castellino et al, 2006). It remains
unknown whether CCR5 endows memory T cells with additional
properties. One such property is the elevated sensitivity of effector
and memory (“antigen-experienced”) CD4+ and CD8+ T cells to
their cognate antigen compared to naı¨ve cells (Kimachi et al, 1997;
Kersh et al, 2003; Huang et al, 2013). This sensitivity gradient
(memory >> effector > naı¨ve) in CD8+ T cells is linked to increased
valency of preformed T-cell antigen receptor (TCR) oligomers at the
cell surface, termed TCR nanoclusters (Kumar et al, 2011). This anti-
gen-independent TCR nanoclustering (Schamel et al, 2005, 2006;
Lillemeier et al, 2010; Sherman et al, 2011; Schamel & Alarcon,
2013) enhances antigenic sensitivity by increasing avidity to multi-
meric peptide-major histocompatibility complexes (Kumar et al,
2011; Molnar et al, 2012) and by allowing cooperativity between
TCR molecules (Martı´nez-Martı´n et al, 2009; Martı´n-Blanco et al,
2018). TCRb subunit interaction with cholesterol (Chol) and the pres-
ence of sphingomyelins (SM) are both essential for TCR nanocluster-
ing (Molnar et al, 2012; Beck-Garcia et al, 2015). Replacement of
Chol by Chol sulfate impedes TCR nanocluster formation and
reduces CD4+CD8+ thymocyte sensitivity to weak antigenic peptides
(Wang et al, 2016). Whether antigen-experienced CD4+ T-cell sensi-
tivity is linked to TCR nanoscopic organization and the homeostatic
factors that regulate TCR nanoclustering remains unexplored.
Given its co-stimulatory role in CD4+ T cells, we speculated that
CCR5 signals would affect the antigenic sensitivity of CD4+ memory
T cells. To test this hypothesis, we analyzed the function of in vivo-
generated memory CD4+ T cells in wild-type (WT) and CCR5/
mice, and the effect of CCR5 deficiency on CD4 T-cell help in the T-
dependent humoral response. We found that CCR5 is necessary for
the establishment of a functional CD4 memory response through a
mechanism independent of its co-stimulatory role for the TCR
signal. We show that CCR5 deficiency does not affect memory CD4
T-cell generation, but reduces their sensitivity to antigen. Our data
demonstrate an unreported CCR5 regulatory role in memory CD4+
T-cell function by inhibiting the synthesis of ceramides, which are
identified here as negative membrane regulators of TCR nanoscopic
organization.
Results
CCR5 deficiency impairs the CD4+ T-cell memory response
To determine the role of CCR5 in CD4+ memory T-cell generation
and/or function, we adoptively transferred congenic CD45.1 mice
with lymph node/spleen cell suspensions from OT-II WT or CCR5/
mice (CD45.2) and subsequently infected them with OVA-encoding
vaccinia virus; 5 weeks post-immunization, we analyzed spleen
CD45.2+ donor cells from OT-II mice. CCR5 expression on OT-II cells
affected neither the total number of memory CD4+ T cells (Fig 1A
and B) nor the percentage of CD4+ TEM (CD44
hi; CD62L; Fig 1C) or
TCM (CD44
hi; CD62L+; Fig 1D) cells generated. OT-II WT cells
nonetheless had stronger responses to antigenic restimulation than
OT-II CCR5/ memory T cells, as determined by the percentage of
interferon (IFN)c-producing cells after ex vivo stimulation with
OVA323–339 (Fig 1E).
We also studied T cell-dependent B-cell responses in WT and
CCR5/ mice after immunization with the hapten 4-hydroxy-3-
iodo-5-nitrophenylacetyl coupled to ovalbumin (NIP-OVA; Fig 1F).
We detected no difference in the percentage or absolute number of
T follicular helper (Tfh) cells (CD4
+, CD44hi, CXCR5+, PD1+)
between WT and CCR5/ mice at 7 days post-immunization
(Fig 1G–I). At day 30, half of the mice were boosted with the same
NIP-OVA immunogen (OVA/OVA) and the other half received NIP
conjugated with another carrier protein (OVA/KLH); levels of NIP-
specific high- and low-affinity immunoglobulins (Ig) were analyzed
15 days later. Comparison of the humoral responses between OVA/
OVA- and OVA/KLH-immunized mice would assess the effect of
memory CD4+ T cells specific for the first carrier protein on the
humoral response to NIP. There were no differences in high/low-
affinity NIP-specific IgM production between WT and CCR5/ mice
with either immunization strategy (Fig 1J and K). CCR5 deficiency
markedly impaired the generation of high-affinity class-switched
anti-NIP antibodies specifically in OVA/OVA-immunized mice
(Fig 1J and K). Since class switching was similar in WT and
CCR5/ OVA/KLH-immunized mice, our results suggest that CCR5
deficiency reduces the generation of high-affinity class-switched
immunoglobulins due to deficient memory CD4+ T-cell function.
The CCR5 effect on antigen-experienced CD4+ T cells is
cell-autonomous
To test whether the in vivo memory defect associated with CCR5
deficiency was intrinsic to CD4+ T cells, we activated OT-II WT and
CCR5/ spleen T cells with OVA323–339 antigen for 3 days; after
antigen removal, we cultured cells with IL-2 or IL-15. OT-II cells that
differentiated in exogenous IL-2 expressed CCL3, CCL4, CCL5, and a
functional CCR5 receptor, as determined by their ability to flux
Ca2+ and migrate after CCL4 stimulation (Appendix Fig S1A–D).
Like CD8+ T cells (Richer et al, 2015), OT-II cells cultured with
IL-15 showed a memory-like phenotype (Fig EV1); they were
smaller than IL-2-cultured cells and retained CD62L with reduced
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Figure 1. CCR5 deficiency impairs CD4+ T-cell memory responses.
A Representative plots of splenocytes from CD45.1 mice adoptively transferred with CD45.2 OT-II WT or CCR5/ lymph node cell suspensions, 5 weeks after infection
with rVACV-OVA virus. The gating strategy used to identify the memory CD4+ T-cell subtypes is shown (n = 5).
B Absolute number of OT-II cells recovered in spleens of mice as in A (n = 5).
C, D Percentage of CD4+ TEM (C) and TCM (D) in the OT-II WT and CCR5
/ populations (n = 5).
E IFNc-producing OT-II WT and CCR5/ memory cells isolated from mice as in (A) and restimulated ex vivo with OVA323–339 (1 lM) (n = 4).
F Immunization scheme for NIP-OVA and NIP-KLH in WT and CCR5/ mice.
G–I Representative plots (G) and quantification of the frequency (H) and absolute number (I) of Tfh cells (CD4
+CD44+PD-1+CXCR5+) in the spleen after primary
immunization (day 7) with NIP-OVA (n = 7).
J, K ELISA analysis of high- (J) and low-affinity (K) isotype-specific anti-NIP antibodies in sera from OVA/OVA- and OVA/KLH-immunized mice (day 15 post-challenge;
n = 5 mice/group). Data representative of one experiment of two.
Data information: (B–E, H–K), Data are mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired Student’s t-test.
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activation marker expression (CD25, CD69, CD44) compared to IL-
2-cultured T cells (Fig 2A). Findings were similar in OT-II WT and
CCR5/ cells (Fig 2B), which reinforced the idea that CCR5 is not
involved in CD4+ T memory cell differentiation. Restimulation of
IL-2- or IL-15-expanded OT-II lymphoblasts with the OVA323–339
peptide nonetheless indicated that CCR5-expressing cells showed
strong proliferation and higher IL-2 production at low antigen
concentrations than CCR5-deficient cells (Fig 2C–F), indicative of an
increased number of cells responding to antigenic stimulation. CCR5
might thus increase the antigenic sensitivity of antigen-experienced
CD4+ T cells in a cell-autonomous manner.
CCR5 modulates TCR nanoclustering in antigen-experienced
CD4+ T cells
The high antigenic sensitivity of antigen-experienced CD8+ T cells
was partially attributed to increased TCR nanoclustering (Kumar
et al, 2011). To determine whether CCR5 deficiency influences TCR
organization, we used electron microscopy (EM) to analyze surface
replicas of OT-II WT and CCR5/ naı¨ve cells and lymphoblasts
after labeling with anti-CD3e antibody and 10 nm gold-conjugated
protein A; a representative image of a IL-15-expanded WT lympho-
blast is shown (Fig EV2). We found no differences in TCR
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Figure 2. CCR5 increases the sensitivity of antigen-experienced CD4+ T cells.
A, B Representative histograms and quantification of mean fluorescence intensity (MFI; A) or the percentage of cells positive for the indicated memory markers (B) in
OT-II WT and CCR5/ lymphoblasts expanded in IL-2 or IL-15, as specified. Data shown as mean  SEM (n ≥ 3). The gating strategy is shown in Fig EV1.
C–F IL-2- (C, D) and IL-15-expanded lymphoblasts (E, F) were restimulated with indicated concentrations of OVA323–339; cell proliferation (thymidine incorporation into
DNA; C, E) and IL-2 production (by ELISA; D, F) were measured after 72 h. Data are presented as mean  SEM (n = 5).
Data information: *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA (B) or two-tailed unpaired Student’s t-test (C–F).
4 of 19 The EMBO Journal e104749 | 2020 ª 2020 The Authors
The EMBO Journal Ana Martín-Leal et al
nanoclusters between OT-II WT and CCR5/ naı¨ve cells, which
had a small percentage of TCR nanoclusters larger than 4 TCR in
both genotypes (Fig 3A). In contrast, there was a significant
increase in TCR nanocluster number and size in WT compared to
CCR5/ lymphoblasts (Fig 3B and C). The number of TCR
nanoclusters per cell analyzed in each condition is also indicated
(Appendix Table S1). As predicted, there was a gradient in TCR
nanoclustering of naı¨ve  IL-2- < IL-15-differentiated OT-II WT
cells (Appendix Fig S1E), which coincided with increased anti-
genic sensitivity of the IL-15-expanded cells (Appendix Fig S1F
and G). These findings thus reinforce the IL-15-induced memory-
like phenotype versus the IL-2-induced effector-like phenotype and
link TCR nanoclustering with increased sensitivity in antigen-
experienced CD4+ T cells. The difference in TCR nanoclustering
between WT and CCR5/ cells was nevertheless similar in IL-2-
and IL-15-expanded lymphoblasts, which indicates that CCR5
affects TCR nanoclustering in lymphoblasts independently of the
cytokine milieu.
Using a Monte Carlo simulation, we applied data from surface
replicas of naı¨ve and IL-2-expanded OT-II lymphoblasts to deter-
mine whether the experimental frequency of cluster size was due
to random distribution of gold particles. In all cases, the cluster
distributions observed experimentally differed significantly from
pure random proximity between clusters (Appendix Fig S2). To
define the differences between OT-II WT and CCR5/ cells, we
used a model that accounts for receptor clustering dynamics (Cas-
tro et al, 2014), a Bayesian inference method that estimates the
so-called clustering parameter, b. Based on this model, we
concluded that the probability of a chance nanocluster distribution
similar to that observed for naı¨ve and activated OT-II WT and
CCR5/ cells approaches 0% (Fig 3D and E). Posterior distribu-
tion analysis also showed that whereas the clustering parameter
was very similar between naı¨ve OT-II WT and CCR5/ cells
(Fig 3D), there was clear separation in lymphoblasts (Fig 3E).
These analyses provide a mathematical framework that validates
the TCR nanoclustering differences between WT and CCR5/
cells, as determined by EM.
The differences in TCR oligomerization between OT-II WT and
CCR5/ lymphoblasts were also studied using blue-native gel
electrophoresis (BN-PAGE) (Schamel et al, 2005; Swamy &
Schamel, 2009). Cell lysis with digitonin, a detergent that disrupts
TCR nanoclusters into their monomeric components, showed that
WT and CCR5/ lymphoblasts expressed comparable TCR levels,
as detected with anti-CD3f antibodies (Fig 3F). Cell lysis with
Brij96, which preserves TCR nanoclusters, showed a notable
reduction in large TCR complexes in CCR5/ compared to WT
lymphoblasts (Fig 3F). Two independent techniques thus support
a CCR5 role in TCR nanoscopic organization in antigen-experi-
enced CD4+ T cells.
To determine whether CCR5 controls TCR nanoclustering in
in vivo-generated memory T cells, we analyzed TCR distribution in
surface replicas of CD4+ memory T cells purified by negative selec-
tion from OVA/OVA-immunized WT and CCR5/ mice
(Appendix Fig S3). CD4+ memory cells from CCR5/ mice showed
fewer, smaller TCR nanoclusters than those from WT counterparts
(Fig 3G; Appendix Table S1), which indicates that CCR5 promotes
formation of large TCR nanoclusters in endogenously generated
CD4+ memory T cells.
CCR5-induced TCR nanoclustering is independent of its
co-stimulatory activity
Since CCR5 has co-stimulatory functions in CD4+ T-cell priming
(Molon et al, 2005; Gonza´lez-Martı´n et al, 2011), it is of interest
to know whether defective TCR clustering in CCR5/ lympho-
blasts is due to suboptimal primary activation of these cells. To
address this question, we treated OT-II WT cells with the CCR5
antagonist TAK-779 at various intervals throughout culture and
analyzed TCR nanoclusters in IL-2-expanded T lymphoblasts.
TAK-779 addition during the priming phase (blockade of CCR5 co-
stimulatory function) decreased the percentage of large TCR
nanoclusters compared to untreated controls (Fig 4A). TAK-779
treatment did not alter TCR clustering in OT-II CCR5/ cells
(Appendix Fig S4), which indicates that the TAK-779 effect on OT-
II cells is CCR5-specific.
To avoid interference with the CCR5 co-stimulatory activity, we
primed OT-II WT cells in the absence of the inhibitor and added
TAK-779 only during IL-2-driven expansion of the CD4+ lympho-
blasts. In these conditions, TAK-779 also reduced the percentage of
large TCR nanoclusters (Fig 4B), which indicates that the CCR5
signals that control TCR organization are independent of those
involved in its co-stimulatory function.
We next explored whether other chemokine receptors involved
in T-cell activation control TCR nanoclusters in CD4+ T cells.
CXCR4 is a paradigmatic chemokine receptor that also provides co-
stimulatory signals (Kumar et al, 2006; Smith et al, 2013). We
primed OT-II WT cells in the presence of the CXCR4 antagonist
AMD3100 and analyzed TCR nanoclusters in IL-2-expanded T
lymphoblasts. Vehicle- and AMD3100-treated cells showed similar
TCR nanocluster distribution (Fig 4D), which implies that CXCR4
blockade does not interfere with TCR nanoclustering.
CCR5 deficiency increases ceramide levels in CD4+ T cells
We analyzed CCR5 regulation of TCR nanoclustering in CD4+ T
cells and found no differences between OT-II WT and CCR5/ cells
in TCR/CD3 chain mRNA levels or in cell surface expression of the
TCRa chain (Fig EV3). These data suggest that the reduction in TCR
clustering in CCR5/ cells is not due to decreased TCR expression.
T-cell antigen receptor nanoclustering is dependent on plasma
membrane Chol and SM (Molnar et al, 2012), two lipids also neces-
sary for CCR5 signaling (Man˜es et al, 2001). OT-II WT and CCR5/
lymphoblasts expressed comparable levels of total Chol and SM
species (Fig 5A and B). OT-II CCR5/ lymphoblasts nonetheless
showed a significant increase in most ceramide (Cer) species and
their dihydroCer (dhCer) precursors (Fig 5C and D). These dif-
ferences were not observed in naı¨ve OT-II WT and CCR5/ cells
(Appendix Fig S5A), indicative that the Cer increase was specific to
antigen-experienced cells. The increase in Cer species in CCR5/
lymphoblasts was not linked to enhanced apoptosis compared to
WT cells (Appendix Fig S5B).
CCR5 deficiency upregulates specific ceramide synthases in
CD4+ T cells
Our analysis of the mRNA levels of key enzymes involved in Cer
metabolism showed no differences in ceramidases (ASAH1, ACER 2,
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ACER 3) and sphingomyelinases (SMPD1–4) between OT-II WT and
CCR5/ naı¨ve cells or lymphoblasts (Fig EV4). mRNA levels of the
ceramide synthases (CerS) CerS2, CerS3, and CerS4 were nonethe-
less upregulated in OT-II CCR5/ lymphoblasts (Fig 5E); CerS5 and
CerS6 were unaltered, and the nervous system-specific CerS1 isoen-
zyme was not detected. CerS2, CerS3, and CerS4 levels were compa-
rable in naı¨ve CD4+ WT or CCR5/ cells (Fig 5E), which again
associate the CCR5 transcriptional effect on these genes with activa-
tion.
We sought to validate the CerS isoforms upregulated by CCR5
deficiency at the protein level. In accordance with mRNA analy-
ses, CerS2 protein levels were significantly higher in CCR5/
than in WT lymphoblasts (Fig 5F); CerS3 and CerS4 were unde-
tectable or only barely detectable by immunoblot. This is
consistent with the fact that CerS2 has the highest expression
level and the broadest substrate specificity in other cell types
(Laviad et al, 2008). Chromatin immunoprecipitation (ChIP),
followed by amplification of a region of the CerS2 promoter
enriched in CpG islands, showed that binding of the transcrip-
tional activation marker acetylated histone H3K9 (H3K9Ac) was
higher in CCR5/ than in WT lymphoblasts (Fig 5G). Moreover,
blockade of CCR5 signaling with pertussis toxin (PTx; an inhi-
bitor of the Gai subunit) also increased CerS2 mRNA expression
(Fig 5H).
To further study CCR5 transcriptional regulation of CerS, we
scanned for transcription factors with putative binding sites in the
CerS2, CerS3, and CerS4 promoters, which are transcriptionally
upregulated in CCR5/ lymphoblasts, but not represented in the
CerS6 promoter, which is not CCR5-regulated. We selected two
regions; region 1 comprised 5 kb to the 50UTR, and region 2
encompassed the 50UTR to the first coding exon (Fig 5I). This bioin-
formatic approach identified GATA-1 and NF-IB (nuclear factor-1B)
as putative transcription factors involved in the differential expres-
sion of the CerS2 isoform (Fig 5J and K).
We focused on GATA-1, since it is implicated in the differentia-
tion of some CD4+ T-cell subtypes (Sundrud et al, 2005; Fu et al,
2012). Immunofluorescence analyses showed increased nuclear
levels of the phosphoSer142-GATA-1 form in OT-II CCR5/
compared to WT lymphoblasts (Fig 5L and M), which correlated
with enriched GATA-1 binding to the CerS2 promoter in CD4+
CCR5/ lymphoblasts (Fig 5N). CCR5 deficiency might induce
CerS2 transcription through GATA-1.
Ceramide levels control TCR nanoclustering
We used a synthetic biology approach to determine whether cera-
mide content affects TCR nanoclustering. Large unilamellar vesicles
(LUV) were prepared at different molar ratios of PC, Chol, SM, and
Cer (Fig 6A) and then reconstituted with a streptavidin-binding-
peptide-tagged TCR purified in its native state from murine M.mf-
SBP (streptavidin-binding peptide) T cells (Swamy & Schamel,
2009). The proteoliposomes were analyzed by BN-PAGE after solu-
bilization in 0.5% Brij96 to maintain TCR nanocluster integrity or in
1% digitonin to disrupt TCR clusters. As anticipated (Molnar et al,
2012; Wang et al, 2016), TCR was monomeric in PC-containing
LUV, whereas it formed nanoclusters when reconstituted in PC/
Chol/SM liposomes (Fig 6B and C). The inclusion of ceramides in
these LUV (PC/Chol/SM/Cer liposomes) reduced TCR nanocluster-
ing in a dose-dependent manner. This effect was not due to differen-
tial TCR reconstitution in Cer-containing LUV, since digitonin
treatment rendered equivalent levels of monomeric TCR in each
condition (Fig 6B). These data suggest that Cer membrane content
impairs TCR nanoclustering.
To test whether this effect also occurs in live cells, we treated
OT-II WT lymphoblasts with recombinant sphingomyelinase
(SMase), which hydrolyzes SM to ceramide (Kitatani et al, 2008).
SMase treatment of WT OT-II blasts increased Cer levels robustly
(Fig 6D), but did not compromise cell viability (Appendix Fig S6).
Analysis of membrane replicas from these cells showed that
SMase treatment reduced the number of high valency TCR
nanoclusters compared to controls (Fig 6E; Appendix Table S1),
which indicates that high Cer levels hinder TCR nanoclustering in
CD4+ T cells.
CerS2 silencing restores TCR nanoclustering after CCR5
functional blockade
To correlate increased CerS2 expression with the impaired TCR
nanoclustering in OT-II CCR5/ T cells, we attempted to silence
CerS2 expression by lentiviral transduction of primary lymphoblasts
with short-hairpin (sh) RNA for CerS2 or control (shCtrl). In the
most successful experiments, we were only able to transduce ~ 20%
of the lymphoblasts, which did not lead to solid CerS2 mRNA silenc-
ing (Appendix Fig S7A and B). Despite the low efficiency, antigenic
restimulation tended to promote stronger responses in shCerS2-
◀ Figure 3. CCR5 increases TCR nanoclustering in antigen-experienced CD4+ T cells.A–C Analysis of TCR nanoclustering by EM in OT-II WT and CCR5/ naïve cells (A; n = 6 cells/genotype; WT: 3,427, CCR5/: 3,528 particles), and IL-2- (B; WT, n = 8
cells, 15,419 particles; CCR5/, n = 6 cells, 5,410 particles) or IL-15-expanded lymphoblasts (C; WT, n = 8 cells, 27,518 particles; CCR5/, n = 7 cells, 22,696
particles). A representative small field image at the top of each panel shows gold particle distribution in the cell surface replicas of anti-CD3e-labeled cells; at
bottom, quantification (mean  SEM) of gold particles in clusters of indicated size in WT (gray bars) and CCR5/ cells (red). Insets show the distribution of
clusters of one, two, three, four, or more than four particles, and statistical analysis.
D, E Posterior distribution in naïve (D) and IL-2-expanded lymphoblasts (E) of the clustering parameter b for WT (gray) and CCR5/ cells (red); randomly generated
distributions of receptors are shown in blue. The mean value of the b parameter is indicated for each condition. The probability of a chance distribution similar to
that determined in cells is nearly 0% by the ROPE.
F Comparison of TCR oligomer size using BN-PAGE and anti-CD3f immunoblotting in day 10, IL-2-expanded WT and CCR5/ OT-II lymphoblasts lysed in buffer
containing digitonin or Brij-96. The marker protein is ferritin (f1, 440 and f2, 880 kDa forms). The ratio of TCR nanoclusters to monomeric TCR in each lysis
condition was quantified by densitometry (right; n = 5).
G Top, representative small field EM images showing gold particle distribution in the cell surface replicas of CD4+ T cells isolated from OVA/OVA-immunized WT and
CCR5/ mice. Bottom, quantification (mean  SEM) of gold particles in clusters of the indicated size (WT, gray bars; n = 5 cells, 14,680 particles; CCR5/, red;
n = 7 cells, 15,374 particles). Insets show the distribution between clusters of one, two, three, four, or more than four particles, and statistical analysis.
Data information: (A–C, F, G), Data are mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-tailed unpaired Student’s t-test. Scale bar, 50 nm (A–C, G).
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than in shCtrl-transduced cells (Appendix Fig S7C and D). The low
efficiency also precluded analysis of TCR nanoclusters in membrane
replicas, as transduced cells could not be distinguished from non-
transduced cells.
To overcome these difficulties, we used the 2B4 CD4+ T-cell
line. We verified that 2B4 cells expressed CCR5 and that TAK-
779 treatment increased CerS2 levels and impaired TCR
nanoclustering (Appendix Fig S8). The data suggest that CCR5
effects on TCR nanoclustering and CerS2 induction are not exclu-
sive to the OT-II system and that TAK-779-treated 2B4 cells
mimic the functional findings in OT-II CCR5/ lymphoblasts.
2B4 cells were transduced efficiently by lentiviruses and, after
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3 days of antibiotic selection, 100% of the cells expressed the
shRNA; this led to strong silencing of CerS2 mRNA and protein
in shCerS2- compared to shCtrl-transduced cells (Fig 6F–H).
Analysis of TCR organization showed recovery of large TCR
nanoclustering in TAK-779-treated, shCerS2-transduced cells
compared to controls (Fig 6I; Appendix Table S1); after restimu-
lation with plate-bound anti-CD3e antibody in the presence of
TAK-779, CD69 upregulation was higher in CerS2-deficient than
in shCtrl-cells (Fig 6J).
CCR5 modulates TCR nanoclustering in human CD4+ T cells
Finally, we tested whether CCR5 deficiency also impairs TCR orga-
nization in human CD4+ T cells. Approximately 1% of the
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Spanish population bears the ccr5D32 polymorphism in homozy-
gosity (Man˜es et al, 2003). Purified CD4+ T cells from healthy
WT or ccr5D32 homozygous donors were activated with anti-CD3
and anti-CD28 antibodies for 3 days and maintained for five addi-
tional days with IL-2. We found that ccr5D32 lymphoblasts had a
lower percentage of large TCR nanoclusters than WT cells (Fig 7A;
Appendix Table S1); concomitantly, the fraction of monomeric
TCR was increased in the former. Sphingolipid analysis of these
CD4+ lymphoblasts showed an increase in saturated 24-carbon
Cer (C24:0) and its precursor (dhCer C24:0) in cells derived from
ccr5D32 donors, whereas SM levels were comparable between
both genotypes (Fig 7B). This increase in Cer levels was associ-
ated with upregulation of CerS2 mRNA in ccr5D32 lymphoblasts
compared to WT controls (Fig 7C); expression of other enzymes
involved in Cer metabolism was unchanged in both genotypes
(Fig EV5). These results indicate that, as found in mouse CCR5/
lymphoblasts, antigen-experienced human CD4+ T cells from
ccr5D32 homozygotes show defective TCR nanoclustering associ-
ated with increased Cer levels and upregulated CerS2. Moreover,
they indicate that these CCR5 effects are not restricted to specific
T-cell clones, but can be observed in a polyclonal T-cell
repertoire.
Discussion
Here, we show that CCR5 signaling is largely dispensable for
memory CD4+ T-cell differentiation, but provides specific signals
that improve the functional fitness of memory cells after antigen re-
encounter. The CCR5 signals optimize TCR nanoclustering and anti-
gen sensitivity by triggering a CD4+ T-cell-specific transcription
program that regulates Cer metabolism. This CCR5 program oper-
ates in murine and human CD4+ T cells, which suggests physio-
pathological relevance.
A central observation of our study is that CCR5 expression
enhances the degree of TCR nanoclustering in resting antigen-
experienced T cells, both in vitro and in vivo. The presence of TCR
nanoclusters in resting T cells was shown by BN-PAGE, EM, and
super-resolution microscopy (Schamel et al, 2005; Hu et al, 2016;
Jung et al, 2016; Pageon et al, 2016). We demonstrate here differen-
tial TCR nanoclustering in WT and CCR5-deficient cells using two
complementary approaches (EM and BN-PAGE), based on different
conceptual principles. In EM, TCR nanoclusters were defined as gold
particle aggregates at < 10 nm distance from one another. Previous
analyses showed that this criterion permits identification of TCR
nanoclusters formed by TCR-TCR interactions (Kumar et al, 2011);
these tightly associated TCR nanoclusters would allow inter-TCR
cooperativity for pMHC binding (Martı´n-Blanco et al, 2018). We
therefore intentionally considered TCR not to be in the same
nanocluster if the gap between them was > 10 nm; this excludes
considering more loosely associated TCR as nanoclusters, but the
strict definition allowed association of TCR nanoclusters to a T-cell
biological function.
It is also important to clarify that gold particle counts do not
necessarily correspond to the number of TCR molecules in a
nanocluster. BN-PAGE defines neither the exact size nor the
abundance of TCR nanoclusters. Direct comparison of CCR5/
with WT cells using both methods nonetheless allowed us to
detect relative differences and determine the promoter effect of
CCR5 in TCR nanoclustering. Application of Monte Carlo simula-
tions further indicated that the nanoclusters observed in EM are
not the result of random proximity of gold particles. The esti-
mated clustering parameter (b) for randomly distributed particles
was virtually zero.
Since CCR5 provides positive signals during activation of
naı¨ve CD4+ T cells (Molon et al, 2005; Nesbeth et al, 2010;
Gonza´lez-Martı´n et al, 2011), we attempted to clarify whether
TCR nanoclustering impairment in CCR5/ cells is solely an
effect of this defective priming. This is unlikely, since TCR clus-
tering was inhibited when CCR5 was blocked during expansion
of fully activated WT lymphoblasts. This effect on TCR nanoclus-
tering during lymphoblast expansion was modest compared to
that observed in the priming phase, but is probably the result of
insufficient CCR5 inhibition during lymphoblast expansion. CCR5
is not only upregulated shortly after activation, but is maintained
in memory CD4+ T cells, which are highly susceptible to
◀ Figure 5. CCR5 deficiency increases Cer levels by upregulating specific CerS.A Total Chol levels in WT and CCR5/ OT-II lymphoblasts (day 10, IL-2-expanded) as determined by a fluorometric assay (n = 6).
B–D SM (B), Cer (C) and dhCer (D) levels in WT and CCR5/ OT-II 10-day lymphoblasts, as determined by UPLC-TOF MS. Values, after normalization with C17 standards
and cell number in each sample, are the mean of two independent experiments (n = 6).
E RT–qPCR determination of CerS mRNA levels in naïve and IL-2-expanded WT and CCR5-/ OT-II 10-day lymphoblasts (n = 3–5).
F Representative immunoblot showing CerS2 protein levels in naïve and WT and CCR5/ OT-II 10-day lymphoblasts, and densitometric quantification of blots as
above (n = 10).
G ChIP analysis of the CerS2 promoter using an anti-H3K9Ac antibody. Scheme of the CerS2 promoter showing CpG islands and primers used for amplification.
Relative ChIP of the CerS2 promoter in WT and CCR5/ OT-II 10-day lymphoblasts (n = 3).
H Relative CerS2 mRNA level in CD4 T cells treated with PTx (n = 3).
I Scheme of a canonical CerS gene to illustrate the in silico strategy used to search for CerS-specific transcription factors.
J, K Venn diagrams showing the number of transcription factors with putative binding sites in the indicated CerS genes in regions 1 (J) and 2 (K). The red circle
highlights the transcription factors shared by CerS2, CerS3, and CerS4 promoters, but not present in the CerS6 promoter.
L Representative immunofluorescence images showing pSer142-GATA-1 staining (green) of OT-II WT and CCR5/ lymphoblasts. The green channel (top) and the
merge with nuclear DAPI staining (blue; bottom) are shown. Scale bar, 10 lm.
M Quantification of nuclear staining of the cells plotted as integrated density fluorescence intensity in DAPI-stained area (n ≥ 50 cells/condition).
N Top, basic scheme of the CerS2 promoter, indicating the putative GATA-1 binding site (blue) and location of the primers used for amplification in ChIP assays (black
arrows). Bottom, relative anti-GATA-1 ChIP levels in OT-II WT and CCR5/ lymphoblasts (n = 5).
Data information: (E, G, H, N), Each data point is the average of triplicates in an independent experiment. (A–H, M, N), Data shown as mean  SEM of triplicates;
*P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired Student’s t-test.
Source data are available online for this figure.
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Figure 6. Cer levels determine the grade of TCR nanoclustering.
A Scheme of the strategy used to form TCR proteoliposomes, and size of LUV generated at the indicated lipid molar ratio. Polydispersity index values are shown as
black squares for each condition (n = 3). SBP, streptavidin-binding-peptide-tagged TCR.
B Representative immunoblots comparing TCR nanocluster sizes via BN-PAGE and anti-CD3f immunoblotting in TCR proteoliposomes lysed in the presence of Brij-96
or digitonin. The marker protein is ferritin (f1, 440 and f2, 880 kDa forms).
C The ratio of the nanocluster and monomeric TCR in each lysis condition was quantified by densitometry from immunoblots as in (B) (n ≥ 4).
D Cer levels in OT-II 10-day lymphoblasts, untreated or treated with SMase (n = 4).
E Representative small field images showing gold particle distribution, and quantification (mean  SEM) of gold particles in clusters of the indicated size in cell surface
replicas from untreated (gray bars; n = 5 cells, 8,126 particles) and SMase-treated (1 h) OT-II lymphoblasts (cyan; n = 6 cells, 8,457 particles) after CD3e labeling, as
determined by EM. The inset shows distribution between clusters of one, two, three, four, or more than four particles.
F GFP expression in shCtrl- (black) and shCerS2 (orange)-transduced 2B4 cells after puromycin selection, as determined by FACS. Non-transfected 2B4 cells (gray).
G Relative CerS2 mRNA levels in TAK-779-treated 2B4 cells as in (F). Values were normalized to those obtained in untransduced TAK-779-treated 2B4 cells (n = 3).
H Representative immunoblot with anti-CerS2 antibody to determine CerS2 protein levels in shCtrl and ShCerS2-transduced 2B4 cells as in (G). Filters were rehybridized
with b-actin as loading control.
I TCR nanoclustering of shCtrl- and shCerS2-transduced 2B4 cells in the presence of TAK-779 as determined by EM. Representative small field images and
quantification (mean  SEM) of gold particles in clusters of indicated sizes in cell surface replicas shCtrl (black bars; n = 6 cells, 12,337 particles) and shCerS2 2B4
lymphoblasts (orange; n = 7 cells, 13,456 particles). Inset, distribution between clusters of indicated size and statistical analysis.
J Percentage of CD69+ shCtrl (black) and shCerS2 (orange) 2B4 cells restimulated with plate-bound anti-CD3e antibody in the presence of TAK-779 (n = 3).
Data information: (A, C–E, G–J), Data are shown as mean  SEM. *P < 0.05, **P < 0.01, one-tailed (E, I) or two-tailed unpaired Student’s t-test. Scale bar, 50 nm.
Source data are available online for this figure.
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infection by R5-tropic HIV-1 strains (Nie et al, 2009). Our results
showed increased CCR5 mRNA expression during lymphoblast
expansion. These lymphoblasts also expressed CCR5 ligands,
suggesting autocrine CCR5 stimulation during this phase. We
thus propose that TCR nanoclustering is regulated by CCR5
signals transduced during lymphoblast differentiation rather than
during priming.
Another feature that distinguishes CCR5 effects on priming and
on TCR nanoclustering is the role of CXCR4 in these events. During
priming, CCR5 and CXCR4 are recruited to and accumulate as
heteromeric complexes at the IS of CD4+ T cells; AMD3100 (a
CXCR4 antagonist) prevented not only CXCR4 but also CCR5 accu-
mulation (Contento et al, 2008), which indicates necessary coopera-
tion between CCR5 and CXCR4 for full T-cell activation. In contrast,
AMD3100 did not affect TCR nanoclusters in CCR5-expessing cells,
which suggests that CXCR4/CCR5 heterodimer signaling is not
essential for TCR nanoclustering in lymphoblasts. CCR5 homo- and
heterodimers are thought to associate differently with Ga subunits;
homodimers signal through the PTx-sensitive Gai, whereas heterodi-
mers generate PTx-resistant responses (Mellado et al, 2001). CCR5
co-stimulatory signals in the IS are PTx-resistant (Molon et al,
2005), consistent with CCR5/CXCR4 heterodimerization during
priming. PTx potentiates transactivation of the CerS2 promoter
(Fig 5H), however, which suggests involvement of the CCR5-
induced Gai pathway in TCR nanoclustering. CCR5 thus appears to
trigger distinct signaling pathways for co-stimulation and TCR
nanoclustering in CD4+ T cells. Since chemokine receptors can form
nanoclusters (Martinez-Mun˜oz et al, 2018), it would be of interest
to study potential feedback loops between TCR and CCR5 nanoclus-
ters.
Cholesterol and SM are two lipids essential for CCR5 signaling
and TCR nanoclustering (Man˜es et al, 2001; Molnar et al, 2012). In
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Figure 7. CCR5 controls TCR nanoclustering and Cer metabolism in human CD4+ cells.
A Analysis of TCR nanoclustering in lymphoblasts from healthy WT and ccr5D32 homozygous donors by EM. Top, representative small field image showing gold particle
distribution in cell surface replicas of anti-CD3e-labeled cells; bottom, quantification (mean  SEM) of gold particles in clusters of the indicated size in the WT (gray
bars; n = 5 cells, 17,689 particles) and D32/D32 cells (light red; n = 4 cells, 16,938 particles). Insets show the distribution between clusters of one, two, three, four, or
more than four particles, and statistical analysis.
B Normalized SM, Cer, and dhCer levels in lymphoblasts obtained as in (A). A representative experiment is shown (n = 3 donors/genotype; n = 2 independent
experiments).
C Relative CerS2 mRNA levels in day 8 WT and ccr5D32 lymphoblasts. Each data point is the average of a technical triplicate from three donors in two independent
experiments (n = 6).
Data information: Data are shown as mean  SEM (B, C). *P < 0.05, **P < 0.01, two-tailed unpaired Student’s t-test. Scale bar, 50 nm.
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resting T cells, these receptors nonetheless partition in different
membrane phases, liquid-ordered (lo) for CCR5 (Molon et al, 2005)
and liquid-disordered (ld) for TCR (Beck-Garcia et al, 2015). This
differential phase segregation argues against direct CCR5/TCR inter-
action as a mechanism that influences TCR nanoclustering. Our
results suggest instead that increased levels of long-chain Cer
species cause defective TCR nanoclustering in CCR5/ lympho-
blasts. Indeed, elevation of Cer levels in TCR-reconstituted proteoli-
posomes and in live cells by SM hydrolysis impaired nanoscopic
TCR organization. Although Cer levels were higher in lymphoblasts
than in naı¨ve cells, which supports a role for Cer in T-cell activation
(Sofi et al, 2017), CCR5 deficiency further increased Cer levels
specifically in lymphoblasts. The Cer increase in CCR5/ lympho-
blasts did not cause spontaneous apoptosis (Appendix Fig S6B),
which coincides with the non-apoptotic and preventive effects of
long-chain Cer in this process (Stiban & Perera, 2015).
Although Cer levels increased in antigen-experienced CD4+ T
cells from CCR5/ mice and ccr5D32 homozygotes, there were dif-
ferences between the mouse and the human cell ceramidome. This
could depend on many factors, including the overall species-specific
enzymes involved in sphingolipid metabolism, or the lipid composi-
tion of the diet. Membrane phase segregation properties of cera-
mides are dependent not only on the saturation, but also on the
length of their acyl chain and the lipid microenvironment that
surrounds them (Alonso & Gon˜i, 2018). Although C24:1 is the most
abundant Cer in mouse WT and CCR5/ T cells, the biggest dif-
ferences associated with CCR5 deficiency were observed for C20:0
and C22:0 Cer. The differential membrane phase segregation proper-
ties of C24:0 and C24:1 Cer might be subtle in an environment
enriched in other long-chain saturated Cer and dhCer.
Several settings can be hypothesized that explain Cer effects on
TCR nanoclustering. In model membranes, Cer has strong segrega-
tion capacity, which might affect their lateral organization (Alonso
& Gon˜i, 2018). When the Chol concentration is saturating, however,
as is the case of cell membranes and our proteoliposomes, Cer-
enriched domains are not formed, due to the ability of Chol and Cer
to displace one another (Castro et al, 2009). This argues against the
idea that Cer impairs TCR clustering by promoting a general reduc-
tion in membrane lateral diffusion. Our mathematical model also
predicted that cluster distribution is independent of TCR diffusivity.
Interaction of the TCRb subunit with Chol/SM complexes is critical
for TCR nanoclustering (Molnar et al, 2012; Wang et al, 2016). High
levels of Cer or their precursors (dhCer) could transform Chol/SM
into Chol/SM/Cer domains with specific physicochemical proper-
ties, which might hinder TCR nanocluster formation physically or
thermodynamically. For instance, high dhSM levels inhibit CCR5-
mediated HIV-1 infection by rigidifying CCR5-containing lo domains
(Vieira et al, 2010). Chol/SM interaction depends on the hydrogen
bond generated by the amide group of the SM molecule and the 3-
hydroxyl group of Chol (Ramstedt & Slotte, 2002), but the SM amide
group can also form hydrogen bonds with the Cer hydroxyl group
(Garcia-Arribas et al, 2016). It is thus possible that, rather than
forming SM/Chol/Cer domains, small increases in Cer levels would
increase the mutual displacement of three lipids. This could lead to
replacement of SM/Chol by SM/Cer complexes with gel-like
biophysical properties (Sot et al, 2008).
Our results indicate that the CCR5 effect on TCR clustering is
biologically meaningful. In a first model, we show that the
responses of CCR5-deficient memory CD4+ T cells generated by
vaccination were impaired after ex vivo stimulation. In a second
model that involves T:B-cell cooperation, we show that CCR5 defi-
ciency impaired class switching of high-affinity antibodies after re-
exposure to a T cell-dependent antigen. Affinity maturation and
class switching depend on recruitment of Tfh cells to GC (Vinuesa
et al, 2016). This Tfh cell confinement is a result of CXCR5 expres-
sion and the downregulation of other homing receptors, including
CCR5 (Crotty, 2011), which could explain the lack of difference in
class switching between OVA/KLH-immunized WT and CCR5/
mice. There were also no differences between WT and CCR5/
effector Tfh cells after the first OVA immunization. Once GC resolve,
however, some Tfh cells are reported to enter the circulation as Tfh
central memory-like cells (Vinuesa et al, 2016). These circulating,
antigen-experienced Tfh cells express CCR5 and are very susceptible
to HIV-1 infection (Xu et al, 2017). We found that the frequency of
large TCR nanoclusters increased in memory T cells from WT
compared to CCR5/ OVA/OVA-immunized mice, which suggests
increased antigenic sensitivity.
We hypothesize that following re-exposure to antigen, CCR5-
expressing memory pre-Tfh cells will have a more efficient response
than CCR5-deficient cells, which would support robust antibody
responses after their differentiation to GC-Tfh cells. In humans, func-
tional CCR5 deficiency does not cause strong immune suppression,
but ccr5D32 homozygosity was associated with four times more fatal
infections than average during the 2009–2011 influenza season in
Spain (Falcon et al, 2015) and fatal infections by the West Nile
Virus in the United States (Lim & Murphy, 2011). Our results
provide a conceptual framework on which to base clinical trials to
evaluate CD4+ T-cell memory responses in CCR5-deficient humans,
and suggest caution regarding the risks associated with genetic abla-
tion of CCR5 as a preventive strategy to block HIV-1 infection.
Material and Methods
Resource Identification Portal accession numbers for antibodies, cell
lines, animals, and other reagents used in the study are provided in
Appendix Table S2.
Antibodies and reagents
Antibodies used to characterize mouse cells by flow cytometry were
anti-Va2TCR-PE (B20.1), anti-CD25-PE (PC61), anti-CD45.2-FITC
(104), anti-CD62L-FITC/APC (MEL-14), anti-CD69-PeCy7 (H1.2F3),
and biotinylated anti-CXCR5 (2G8) from BD Biosciences; anti-
human biotinylated CD3 (OKT3), anti-CD4-PeCy7/eFluor450/Pacific
Blue (RM4.5), anti-IFNc-APC (XMG1.2), and anti-PD1-eFluor780
(J43) from eBioscience; and anti-CD44-PeCy5/APC (IM7) from
BioLegend. Biotinylated and purified anti-CD3e (145-2C11; BD Bios-
ciences) were used for EM and T-cell activation, respectively. Anti-
mouse CerS-2 (1A6; Novus Biologicals), anti-CD3f (449, purified
from hybridoma), and anti-b-actin (AC-15; Sigma-Aldrich) were
used for immunoblot. Anti-mouse GATA-1 (D52H6; Cell Signaling)
and anti-mouse phospho-GATA1pSer142 (Thermo Fisher Scientific)
were used for immunofluorescence. Anti-GATA1 (ab11852, Abcam),
anti-histone H3Lys9 (CS200583), and purified IgG rabbit (PP64B;
EMD Millipore) were used for ChIP.
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The OVA323–339 peptide was synthesized at the CNB Proteomics
facility. TAK-779, AMD-3100, poly-L-lysine, pertussis toxin, Cer
(bovine spinal cord), and sphingomyelinase (Bacillus cereus) were
from Sigma-Aldrich. mCCL4, mIL-2, and mIL-15 were from Pepro-
Tech; NIP-KLH, NIP-OVA, NIP(7)-BSA, and NIP(41)-BSA were from
Biosearch Technology. Soybean phosphatidylcholine Chol, egg SM,
C12 Cer (d18:1/12:0), C16 Cer (d18:1/16:0), C18 Cer (d18:1/18:0),
C24 Cer (d18:1/24:0), C24:1 Cer (d18:1/24:1(15Z)), C16 dhCer
(d18:0/16:0), C18 dhCer (d18:0/18:0), C24 dhCer (d18:0/24:0),
C24:1 dhCer (d18:0/24:1(15Z)), C12:0 SM (d18:1/12:0), C16:0 SM
(d18:1/16:0), C18:0 SM (d18:1/18:0), C24:0 SM, C24:1 SM, and the
Cer mix from bovine spinal cord were from Avanti Polar Lipids.
Lentiviral pGIPZ containing shRNAs for murine Cers 2
(V3LMM_454307, V3LMM_454309, and V3LMM_454311 clones),
and the mismatched control were from Dharmacon.
Mice and cell lines
C57BL/6J WT and CCR5/ mice were from The Jackson Labora-
tory. TCR transgenic OT-II CCR5/ mice, recognizing OVA323–339
(ISQAVHAAHAEINEAGR; I-Ab MHC class II molecule), have been
described (Gonza´lez-Martı´n et al, 2011). B6-SJL (Ptprca Pepcb/
BoyJ) mice bearing the pan-leukocyte marker allele CD45.1 were
used for adoptive transfer experiments. CD3e-deficient mice (DeJar-
nette et al, 1998) were used as a source of antigen-presenting cells
for restimulation assays. Mice were maintained in SPF conditions in
the CNB and CBM animal facilities, in accordance with national and
EU guidelines. All animal procedures were approved by the CNB
and the Comunidad de Madrid ethical committees (PROEX 277/14;
PROEX 090/19). Human embryonic kidney HEK-293T cells and the
murine 2B4 hybridoma and its derivative M.mf-SBP (which
expresses a SBP-tagged form of CD3f) (Swamy & Schamel, 2009)
were cultured in standard conditions.
Isolation and culture of mouse and human primary T cells
Spleen and lymph nodes from 6- to 12-week-old OT-II WT and
CCR5/ mice were isolated and cell suspensions obtained using
40-lM pore filters. Erythrocytes were lysed with AKT lysis buffer
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), and cells were acti-
vated with the appropriate OVA peptide for 3 days. Antigen was
removed, and cells were cultured with IL-2 (5 ng/ml) or IL-15
(20 ng/ml). For some experiments, naı¨ve OT-I and OT-II cells were
obtained by negative selection using the Dynabeads Untouched
Mouse CD4 Cell Kit (Thermo Fisher). Flow cytometry indicated
> 85% enrichment in all cases. Memory CD4+ T cells, generated
in vivo after NIP-OVA or NIP-KLH immunization (see below), were
isolated by negative selection with the Mouse Memory T cell CD4+/
CD62L/CD44hi Column Kit (R&D Systems).
Blood samples from ccr5D32 homozygous and WT healthy
donors were from the Fundacio´ ACE (Barcelona, Spain) and
obtained with informed consent of the donors. No personal data
were registered, and all procedures using these samples were in
accordance with the standards approved by the Ethics Committee of
the Hospital Clinic Barcelona (HCB/2014/0494 and HCB/2016/
0659). Human peripheral blood mononuclear cells (PBMC) were
isolated from Vacutainer Cell Preparation Tubes by separation on a
Ficoll gradient. CD4+ T cells were obtained by negative selection
using the EasySep Human CD4+ Enrichment kit (Stem Cell Tech-
nologies) and stimulated with anti-CD3-coated magnetic beads
(Dynabeads M-450 tosyl-activated, Thermo Fisher) for 3 days.
Beads were removed with a magnet, and cells were incubated with
IL-2 (5 ng/ml) to generate lymphoblasts. The ccr5D32 polymor-
phism (rs333) was genotyped by PCR (AriaMx Real-time; Agilent
Technologies) as described (Man˜es et al, 2003).
Flow cytometry
For cell surface markers, cell suspensions were incubated (20 min,
4°C) with the indicated fluorochrome-labeled or biotinylated mono-
clonal primary antibodies in phosphate-buffered saline with 1%
BSA and 0.02% NaN3 (PBS staining buffer). For intracellular label-
ing, cells were fixed and permeabilized with IntraPrep (Beckman
Coulter), followed by intracellular staining with indicated antibod-
ies. Cells were analyzed on Cytomics FC500 or Gallios cytometers
(both from Beckman Coulter) and data analyzed using FlowJo soft-
ware.
Immunization and adoptive transfer
Spleen and lymph node cell suspensions from OT-II WT or CCR5/
cells were adoptively transferred (5 × 106 cells/mouse) into CD45.1
mice. The following day, recipient mice were infected intravenously
with rVACV-OVA virus (2 × 106 pfu). Mice were sacrificed 35 days
later, and splenocyte suspensions were obtained as described
above.
C57BL/6J or CCR5/ mice were immunized (i.p.) with NIP-
OVA (200 lg) in alum (100 ll) diluted 1:1 in PBS. At 7 days post-
immunization, spleens from three mice of each genotype were
harvested and analyzed by flow cytometry to detect Tfh cells. On
day 30, mice were randomized in a blind manner and half of the
mice in each group were re-immunized with NIP-OVA/alum (as
above); the other half received NIP-KLH (200 lg)/alum. Mice were
sacrificed 15 days later, and serum anti-NIP antibodies were deter-
mined by ELISA. Plate-bound NP(7)-BSA and NP(41)-BSA (5 lg/
ml) were used to measure high- and low-affinity Ig, respectively.
Sera from NIP-OVA- and NIP-KLH-immunized mice were diluted
1:175, and, after several washing steps, anti-NIP antibody binding
was developed with the SBA Clonotyping System-HRP (Southern
Biotech). Absorbance at 405 nm was determined in a FilterMax F5
microplate reader (Molecular Devices). Memory cells from NIP-
OVA- and NIP-KLH-immunized mice were purified as indicated and
processed for EM.
Immunogold labeling, replica preparation, and EM analysis
Immunogold-labeled cell surface replicas were obtained as
described (Kumar et al, 2011). Briefly, T cells were fixed in 1%
paraformaldehyde (PFA) and labeled with anti-mouse CD3 mAb
(145-2C11) or anti-human CD3 mAb OKT3, followed by 10 nm
gold-conjugated protein A (Sigma-Aldrich). Labeled cells were
adhered to poly-L-lysine-coated mica strips and fixed with 0.1%
glutaraldehyde. Samples were covered with another mica strip,
frozen in liquid ethane (KF-80, Leica), and stored in liquid nitro-
gen. Cell replicas were prepared with a Balzers 400T freeze frac-
ture (FF) unit, mounted on copper grids, and analyzed on a
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JEM1010 electron microscope (Jeol, Japan) operating at 80 kV.
Images were taken with a CCD camera (Bioscan, Gatan, Pleasan-
ton, CA) and processed with TVIPS software (TVIPS, Gauting,
DE). EM images were collected by two researchers, one of them
blind to the experiment. Gold particles were counted on the
computer. When distance between gold particles was smaller than
their diameter (10 nm), they were considered part of the same
cluster.
BN-PAGE analysis of TCR clustering
Membrane fractions from OT-II WT and CCR5/ cells (20 × 106)
were prepared with a Dounce homogenizer, followed by incubation
in hypotonic buffer (10 mM HEPES pH 7.4, 42 mM KCl, 5 mM
MgCl2, protease inhibitors). Membranes were recovered by ultracen-
trifugation (100,000 g, 45 min, 4°C) and lysed in 150 ll BN lysis
buffer (500 mM Bis-Tris 40 mM pH 7.0, 1 mM e-aminocaproic acid,
40 mM NaCl, 20% glycerol, 4 mM EDTA, and 0.5% Brij96 or 1%
digitonin) with protease inhibitors. BN-PAGE gradient gels (4–8%)
were prepared and used as described (Swamy & Schamel, 2009),
using ferritin 24-mer and 48-mer (f1, 440 kDa; f2, 880 kDa) as
protein markers. Proteins were transferred to PVDF membranes and
probed with anti-CD3f antibody.
Restimulation assays
Splenocytes from CD3e/ mice were irradiated (15 Gy), seeded
(0.6 × 105 cells/well), and loaded (2 h, 37°C) with different
concentrations of OVA323–339 peptide. After centrifugation (300 g,
5 min), isolated lymphoblasts (0.75 × 105 cells/well) were co-
cultured for 48 h. Supernatants were collected to measure IL-2 by
ELISA (ELISA MAX Deluxe, BioLegend) and proliferation was
assessed by methyl-3[H]-thymidine (1 lCi/well) incorporation into
DNA, in a 1450 Microbeta liquid scintillation counter (Perki-
nElmer).
TCR purification
The TCR fused to streptavidin-binding peptide was purified from
M.mf-SBP cells. Briefly, 100 × 106 cells were lysed in lysis buffer
(20 mM Bis-Tris pH 7, 500 mM f-aminocaproic acid, 20 mM NaCl,
2 mM EDTA, 10% glycerol, 1% digitonin). After incubation of the
lysate with streptavidin-conjugated agarose (overnight, 4°C), the
TCR was eluted by incubating samples with 2 mM biotin in lysis
buffer (30 min, 4°C).
Preparation of large unilamellar vesicles and TCR reconstitution
Large unilamellar vesicles with a custom lipid composition were
prepared by the thin film method (Molnar et al, 2012), followed
by extrusion through polycarbonate membranes with a pore size
of 200 nm (21 times) and 80 nm (51 times). The diameter of the
resulting LUV was determined by dynamic light scattering (Zeta-
master S, Malvern Instruments). The LUV preparation (2 mM)
was mixed with purified TCR (0.1 lg) in 100 ll saline-phosphate
buffer with 0.02% Triton X-100, and 40 ll 0.01% Triton X-100
was added. Samples were agitated (30 min, 4°C), and detergent
was removed by adsorption to polystyrene Bio-Beads SM-2 (3 mg;
Bio-Rad; overnight, 4°C). Proteoliposomes were collected by ultra-
centrifugation (180,000 g, 4 h, 4°C), lysed, and analyzed by BN-
PAGE as above.
Sphingolipid and Chol quantification
Total Chol level was measured with the Amplex Red Cholesterol
Assay Kit (Invitrogen) after lysis (50 mM Tris–HCl pH 8; 150 mM
NaCl, 1% NP-40). Sphingolipid determinations were performed by
an external researcher blind to the experimental groups. Prior to
sphingolipid quantification, calibration curves were prepared with
mixtures of C12Cer, C16Cer, C18Cer, C24Cer, C24:1 Cer,
C16dhCer, C18dhCer, C24dhCer, C24:1dhCer, C12SM, C16SM,
C18SM, C24SM, and C24:1SM. For sphingolipid determination,
cell pellets (1 × 106) were mixed with internal standards (N-dode-
canoyl-sphingosine, N-dodecanoylglucosylsphingosine, N-dodeca-
noyl-sphingosylphosphorylcholine, C17-sphinganine, and C17-
sphinganine-1 phosphate; 0.2 nmol each; Avanti Polar Lipids) in a
methanol:chloroform solution. Sphingolipids were extracted as
described (Merrill et al, 2005), solubilized in methanol, and
analyzed by ultra-performance liquid chromatography (UPLC;
Waters, Milford, MA) connected to a time-of-flight detector (TOF;
LCT Premier XE) controlled by Waters/Micromass MassLynx soft-
ware. Lipid species were identified based on accurate mass
measurement with an error < 5 ppm, and their LC retention time
was compared with the standard ( 2) (Mun˜oz-Olaya et al,
2008).
SMase treatment
All experiments (sphingolipid quantification, apoptosis, and TCR
nanoclustering) were performed by incubating OT-II WT and
CCR5/ cells (0.2 × 106) with recombinant sphingomyelinase from
Bacillus cereus (0.5 U/ml; 1 h, 37°C) in serum-free medium. Cells
were washed and processed immediately for EM analysis or for
sphingolipid quantification as above.
Quantitative RT–PCR analyses
Total RNA was extracted from human or murine cells using the
RNeasy Mini Kit (Qiagen), and cDNA was synthesized from 1 lg
total RNA (High Capacity cDNA Reverse Transcription Kit,
Promega). Quantitative RT–PCR was performed using FluoCycle II
SYBR Master Mix (EuroClone) with specific primers
(Appendix Table S3) in an ABI 7300 Real-Time PCR System
(Applied Biosystems). Results were analyzed using SDS2.4 soft-
ware.
CerS2 silencing
Lentiviruses were produced in HEK-293T cells after co-transfection
with pGIPZ-shRNA-CerS2 or control plasmids, pSPAX2 and pMD2.G
(VSV-G protein) using LipoD293tm (SignaGen). Supernatants were
concentrated by ultracentrifugation and supplemented with poly-
brene (8 lg/ml). Lymphoblasts (3 days post-activation) or 2B4 cells
(1.5 × 106 cells/ml) were resuspended in lentiviral supernatant and
centrifuged (900 g, 90 min, 37°C). Transduction efficiency was
analyzed after 24 h by FACS. In the case of 2B4 cells, transduced
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cells were selected with puromycin (2 lg/ml) for 3 days prior to
analyses.
Immunofluorescence analyses
OT-II 10-day WT or CCR5/ lymphoblasts were plated in poly-L-
lysine-coated coverslips (Nunc Lab-Tek Chamber Slide, Thermo
Scientific; 50 lg/ml, overnight, 4°C). After adhesion (1 h, 37°C),
cells were fixed in 4% PFA (10 min), Triton-X100-permeabilized
(0.3% in PBS, 15 min), and blocked with BSA 0.5% in PBS.
Samples were incubated (overnight, 4°C) with anti-mouse phospho-
GATA1pSer142 antibody (1/200), followed by anti-rabbit Ig Alexa-488
secondary antibody (1 h). Coverslips were mounted in Fluoro-
mount-G with DAPI (Southern Biotech); images were acquired with
a Zeiss LSM710 and analyzed by a blind observer with NIH ImageJ
software.
ChIP assay
Chromatin immunoprecipitation assays were performed with the
EZ-ChIP Kit (Millipore). In brief, OT-II WT or CCR5/ lympho-
blasts (2 × 107) were fixed (1% PFA, 10 min, RT) and quenched
(125 mM glycine, 5 min, RT). Cells were harvested (1 × 107 cells/
ml), lysed (15 min, 4°C), and DNA sheared by sonication (45
cycles; 30 s on/off; Bioruptor Pico, Diagenode) in aliquots (0.2 ml).
Of each lysate, 1% was stored as input reference, and the remain-
ing material was immunoprecipitated (14 h, 4°C, with rotation)
with antibodies to GATA1, histone H3-Lys9, or purified IgG (con-
trol). Immune complexes were captured using Protein G Magnetic
Beads (Bio-Rad) and, after washing, eluted with 100mM NaHCO3,
1% SDS; protein/DNA bonds were disrupted with proteinase K
(10 lg/ll, 2 h, 62°C). DNA was purified using spin columns, and
Cers2 gene promoter sequences were analyzed with specific
primers (Appendix Table S3). The relative quantity of amplified
product in the input and ChIP samples was calculated (Mira et al,
2018).
Cell migration and Ca2+ flux assays
OT-II WT or CCR5/ lymphoblasts (106) were added to the upper
chamber of a Transwell (3-lm pore; Corning) and allowed to
migrate toward 100 nM CCL4 for 4 h. Migrating cells were quanti-
fied by flow cytometry (Cytomics FC500). Mobilization of intracellu-
lar Ca2+ stores after CCL4 (100 nM) stimulation was measured as
reported (Go´mez-Mouto´n et al, 2015).
Mathematical and Bayesian analyses
To analyze cluster size distribution, we used a standard chi-square
test to compare the fraction of clusters of a given size (1, 2, 3, etc.)
in each dataset. In all plots, “Random” refers to synthetic distribu-
tions of receptors generated randomly.
To quantify the mechanistic relevance of cluster size between
random distributions of clusters and clusters in WT and in
CCR5/ CD4+ T cells, we used a Bayesian inference model on
top of a mechanistic model (Castro et al, 2014). The model
assumes that TCR aggregates by incorporating one receptor at a
time, with on and off rates that depend on the diffusion
properties of the receptor on the membrane, but not existing clus-
ter size. That is,
1 
q
qþ
2 
q
qþ
3 
q
qþ
. . . 
q
qþ
n 1 q
qþ
n 
q
qþ
nþ 1. . .
The “affinity” of the process is given by b = q+/q, which we
also refer to as the clustering or affinity parameter. In the steady
state, we can calculate analytically the fraction of clusters of a given
size n:
pn ¼ b
n1 1 bð Þ
1 bNmaxð Þ
with
b\ 1; n  1; 2; 3; . . .;Nmaxf g:
The model was fitted using the Bayesian JAGS code (Kruschke,
2014) (see Appendix Supplementary Methods). The histograms for
the number of clusters of a given size n (Nn) were modeled as a
multinomial distribution with the number of observations, N, given
by the total count per experiment, and probabilities pn given by the
formulas above. The priors for the clustering parameter b are beta
distributions with shape parameters A and B with non-informative
uniform priors. Specifically,
Nn ~ Multinomial (pn, N)
b ~ Beta (A, B)
A ~ Uniform (0, 1,000)
B ~ Uniform (0, 1,000)
Posterior distribution of the estimated clustering parameter, b,
is given with the so-called Region of Practical Equivalent (ROPE),
defined as the probability of a parameter from a dataset to be
explained by another dataset. ROPE quantifies the probability
that the observed clustering parameter (and distribution of clus-
ters) in the experiment can be obtained by pure random proxim-
ity.
At the molecular level, the kinetic rates q+ and q can be
expressed in terms of the diffusion rates of the receptors,k
þ=
d , the
receptor size (a), the mean distance between receptors (s), and the
correct receptor–receptor binding rates, k+/, through the equations
(Lauffenburger & DeLisi, 1983):
qþ ¼ k
þ
d k
þ
kþd þ k
q ¼ k

d k

kþd þ k
) b ¼ k
þ
d k
þ
kd þ k
with
kþd ¼
4pD
log s=að Þ  3=4 k

d ¼
2pD
s2 log s=að Þ  3=4ð Þ :
The clustering parameter b is independent of the TCR diffusivity
(as D is canceled), so the observed TCR nanoclustering differences
for WT and CCR5/ cells would be due to TCR-TCR interactions,
as previously reported (Beck-Garcia et al, 2015).
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Identification of transcription factors in CerS promoters
Cers2, Cers3, Cers4, and Cers6 gene coordinates were obtained from
the UCSC Genome browser (https://genome.ucsc.edu/; mouse
genome version GRCm38/mm10). Known transcription factors for
these genes were identified at GTRD v17.04 (http://gtrd17-04.b
iouml.org/). Venn diagrams were constructed to identify common
and specific transcription factors for ceramide synthase genes.
Statistical analyses
For comparison between two conditions, data were analyzed using
parametric Student’s t-tests, paired when different treatments were
applied to the same sample, or unpaired with Welch’s correction.
Multiple parametric comparisons were analyzed with one-way
ANOVA with Bonferroni’s post-hoc test. The chi-square test was
used to analyze overall distribution of gold particles. F test was used
to compare variances. All analyses were performed using Prism 6.0
or 7.0 software (GraphPad). Differences were considered significant
when P < 0.05.
Data and code availability
This study includes no data deposited in external repositories. The
authors confirm that all relevant data and materials supporting the
findings of this study are available on reasonable request. This
excludes materials obtained from other researchers, who must
provide their consent for transfer. The Bayesian JAGS code gener-
ated in the study is provided as supplementary information in the
Appendix Supplementary Methods.
Expanded View for this article is available online.
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Appendix Figure S1. Characterization of CD4+ T lymphoblasts. A. CCR5 ligand levels in 
supernatants of day 10 IL-2-expanded OT-II WT and CCR5-/- lymphoblasts. Data shown as mean ± 
SEM (n = 4). B. Relative CCR5 mRNA levels in OT-II WT lymphoblasts. mRNA was not detected 
in OT-II CCR5-/- lymphoblasts. C. Time course of intracellular Ca2+ mobilization in response to 
CCL4 in OT-II WT and CCR5-/- lymphoblasts. Cells were finally treated with ionomycin as a 
positive control of Ca2+ loading (n = 3). D. Analysis of OT-II WT and CCR5-/- lymphoblast transmi-
gration in transwell chambers, using CCL4 as chemoattractant (solid bars) or in basal medium 
(dashed bars). Data are the percentage of migrating cells relative to total cells seeded. E. EM 
analysis of TCR nanoclustering in OT-II WT naïve cells and lymphoblasts expanded in IL-2 or 
IL-15. Top, representative small field images showing gold particle distribution in the cell surface 
replicas of anti-CD3ε-labeled cells. Bottom, quantification (mean ± SEM) of gold particles in 
clusters of the indicated size in the IL-2- (gray bars; n = 6 cells, 27518 particles) and IL-15-
expanded lymphoblasts (black; n = 8 cells, 27518 particles). Insets show the distribution between 
clusters of one, two, three, four or more than four particles, and statistical analysis. F, G. IL-2- and 
IL-15-expanded OT-II WT lymphoblasts were restimulated with the indicated concentrations of 
OVA323-339; cell proliferation measured by thymidine incorporation into DNA (F) and IL-2 produc-
tion measured by ELISA (G) were determined after 72 h of stimulation. Data shown as mean ± 
SEM (n = 5). * p <0.05, ** p <001, *** p <0.001,  two-tailed unpaired Student’s t-test. Bar, 50 nm.
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Appendix Figure S2. Comparison of experimental and synthetic TCR multimer 
distributions. Percentage of clusters of size n (1 to 9) in WT and CCR5-/- OT-II naïve 
cells and lymphoblasts (day 10) determined experimentally (dark bars), and syntheti-
cally random generated receptors (light bars). Student's t-test significance for each 
cluster size is shown above bars (p >0.05 (not significant), * p <0.05, **p <0.01, *** 
p <0.001). In all cases, the experimental distributions of clusters differ significantly 
from random proximity between clusters.
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Appendix Figure S3. Characterization of endogenous memory CD4+ T cells uses for 
electron microscopy studies. Scheme of the purification of memory cells from OVA/OVA-
immunized  mice as well as a representative plot showing the characterization of the purified 
cells by flow cytometry. 
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Appendix Figure S4. TAK-779 does not affect TCR nanoclustering in 
CCR5-/- lymphoblasts. OT-II CCR5-/- cells were activated with OVA323-339 for 3 
days in the presence of TAK-779, and lymphoblasts were generated by expan-
sion with IL-2. Top, representative small field images showing gold particle 
distribution in cell surface replicas of anti-CD3ε-labeled cells. Bottom, quantifi-
cation (mean ± SEM) of gold particles in clusters of the indicated size in 
vehicle-treated (gray bars; n = 6 cells, 5138 particles) and TAK-779-treated 
lymphoblasts (black; n = 5 cells, 4215 particles). Insets, distribution between 
clusters of one, two, three, four or more than four particles, and statistical 
analysis. * p <0.05, one-tailed unpaired Student’s t-test. Bar, 50 nm.
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Appendix Figure S5. Analysis of sphingolipids and apoptosis in WT and CCR5-/- naïve OT-II cells. A. 
Cer (top), dhCer (center) and SM (bottom) levels in WT and CCR5-/- OT-II naïve cells. Values were normali-
zed to the C17 standards and to cell number in each sample (n = 4). No significant differences were found 
between genotypes in any lipid species (two-tailed unpaired Student’s t-test). B. Representative dot plots of 
WT and CCR5-/- OT-II naïve cells and IL-2 lymphoblasts at days 7 and 10, stained for the apoptosis markers 
7-aminoactinomycin D (7-AAD) and annexin-V. Numbers represent the percentage of cells. The graph shows 
the quantification of doubled-stained cells in different experiments (bottom). Data are mean ± SEM (n = 4). 
No differences were found between genotypes (two-tailed unpaired Student’s t-test). 
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Appendix Figure S6. SMase treatment does not trigger apoptosis in 
lympholasts. Day 10 OT-II lymphoblasts were treated with SMase (0.5 
U/ml, 1 h, 37ºC) and apoptosis determined by FACS analysis after staining 
with annexin-V and propidium iodide (PI). Plots shown for untreated (left) 
and SMase-treated cells (right) in a representative experiment (n = 4).
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Appendix Figure S7. CerS2 silencing in primary CD4+ lymphoblasts. A. Histo-
grams showing GFP staining in shCtrl- (black line) and shCerS2-transduced OT-II 
CCR5-/- lymphoblasts (orange). Data for cells stained at 72 h post-transduction in a 
representative experiment. Gray area represents staining of non-transduced cells 
(negative control). The percentage of GFP+ cells is indicated. B. Relative CerS2 
mRNA levels in cells as in A. C, D. Determination of thymidine incorporation into 
DNA (C) and IL-2 levels (D) in the supernatant of shCtrl- (black line) and shCerS2-
transduced (orange line) OT-II CCR5-/- lymphoblasts restimulated for 48 h with 
OVA323-339 at the indicated concentrations. For B-D, data shown as mean ± SEM (n = 
3). * p <0.05, two-tailed unpaired Student’s t-test.
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Appendix Figure S8. CCR5 blockade also impairs TCR nanoclustering in 
the CD4+ T cell hybridoma 2B4. A, B. Relative mRNA levels of CCR5 (A) and 
CerS2 (B) in CD3ε-activated 2B4 cells untreated (gray bars) or TAK-779-
treated (10 µM; pink). C. Quantification (mean ± SEM) of gold particles in 
clusters of the indicated size in cell surface replicas of anti-CD3ε-labeled 
untreated (gray bars; n = 5 cells, 13266 particles) and TAK-779-treated 2B4 
cells (black; n = 6 cells, 17654 particles). Insets show the distribution between 
clusters of one, two, three, four or more than four particles, and statistical 
analysis. * p <0.05, one-tailed unpaired Student’s t-test.
 
 
 
Appendix Table S1. Number of TCR nanoclusters/cell in the different experiments 
Experiment Cell type Genotype or treatment 
TCR 
nanoclusters/cell n 
Fig. 3A Naïve OT-II cells 
WT 68.3 ± 13.25 6 
CCR5-/- 54 ± 6.7 6 
 
Fig. 3B IL-2-expanded OT-II lymphoblasts 
WT 379.9 ± 49.1 8 
CCR5-/- 163.3 ± 36 6 
 
Fig. 3C IL-15-expanded OT-II lymphoblasts 
WT 600.9 ± 47.3 8 
CCR5-/- 364 ± 53.6 7 
Fig. 3G Purified memory 
CD4+ T cells 
WT 494.5 ± 84.9 5 
CCR5-/- 351.4 ± 47.3 7 
Fig. 4A IL-2-expanded OT-II 
lymphoblasts 
Medium 323.1 ± 58.5 5 
TAK-779 142.5 ± 22.3 6 
Fig. 4B IL-2-expanded OT-II 
lymphoblasts 
Medium 211.5 ± 53.1 5 
TAK-779 195,6 ± 20,3 6 
Fig. 4C IL-2-expanded OT-II 
lymphoblasts 
Vehicle 309.6 ± 65.9 6 
AMD3100 378.7 ± 74.5 7 
Fig. 6E IL-2-expanded OT-II 
lymphoblasts 
Untreated 234.1 ± 58.1 5 
SMase-treated 208.5 ± 19.1 6 
Fig. 6I 2B4 transduced cells 
shCtrl 90.2 ± 16.5 6 
shCerS2 216 ± 63.7 7 
Fig. 7A Human CD4+ T cell 
lymphoblasts 
WT 539.9 ± 80.4 5 
ccr5Δ32 337.7 ± 172 4 
Nanoclusters are defined as aggregates of gold particles >2. n, number of cells analyzed.  
Data are mean ± SEM. 
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Appendix Table S2. RRID accession number and catalog reference of the reagents  
 
REAGENT  SOURCE IDENTIFIER 
Antibodies 
Anti-mouse Vα2TCR-PE (B20.1) BD-Biosciences Cat# 553289, RRID:AB 394760 
Anti-mouse CD25-PE (PC61) BD-Biosciences Cat# 553866, RRID:AB 395101 
Anti-mouse CD45.2-FITC (104) BD-Biosciences Cat# 561874,RRID:AB 10894189 
Anti-mouse CD62L-FITC (MEL-14) BD-Biosciences Cat# 553150,RRID:AB 394665 
Anti-mouse CD62L-APC (MEL-14) BD-Biosciences Cat# 553152,RRID:AB 398533 
Anti-mouse CD69-PeCy7 (H1.2F3) BD-Biosciences Cat# 552879,RRID:AB 394508 
Anti-mouse CXCR5 biotinylated (2G8) BD-Biosciences Cat# 551960,RRID:AB 394301 
Anti-mouse biotin CD3ε (145-2C11) BD-Biosciences Cat# 553239,RRID:AB 394728 
Anti-mouse unlabeled CD3ε (145-2C11) BD-Biosciences Cat# 553057,RRID:AB_394590 
Anti-human biotin CD3 (OKT3) Thermo Fisher 
Scientific 
Cat# 13-0037-80, RRID:AB_1234956 
 
Anti-mouse CD4-PeCy7 (RM4.5) Thermo Fisher 
Scientific 
Cat# 25-0042-81, RRID:AB_469577 
Anti-mouse CD4-efluor450 (RM4.5) Thermo Fisher 
Scientific 
Cat# 48-0042-80, RRID:AB_1272231 
Anti-mouse CD4-PacificBlue (RM4.5) Thermo Fisher 
Scientific 
Cat# MCD0428, RRID:AB_10372505 
Anti-mouse IFNg-APC (XMG1.2) Thermo Fisher 
Scientific 
Cat# 17-7311-82, RRID:AB_469504 
Anti-mouse PD1-efluor780 (J43) Thermo Fisher 
Scientific 
Cat# 47-9985-82, RRID:AB_2574002 
Anti-mouse phospho-GATA1-pSer142 Thermo Fisher 
Scientific 
Cat# PA5-37581, RRID:AB_2554189 
Anti-mouse CD44-Pe/Cy5 (IM7) BioLegend Cat# 103009, RRID:AB_312960 
Anti-mouse CD44-APC (IM7) BioLegend Cat# 103011, RRID:AB_312962 
Anti-mouse CerS2 (1A6) Novus Biologicals Cat# H00029956-M01A, 
RRID:AB_2132954 
Anti-mouse CerS3 (6C12) Novus Biologicals Cat# H00204219-M02 
Anti-mouse CerS6 Novus Biologicals Cat# H00253782-M01, 
RRID:AB_2133107 
Anti-mouse CerS4 (polyclonal) Sigma-Aldrich Cat# SAB4503164, 
RRID:AB_10746317 
Anti-mouse CD3ζ (449) Purified from 
hybridoma, this study 
N/A 
Anti-mouse β-actin (AC-15) Sigma-Aldrich Cat# A1978, RRID:AB_476692 
Anti-mouse GATA1 (ab11852) Abcam Cat# ab11852, RRID:AB_298635 
Anti-acetyl histone H3Lys9 (CS200583) EMD-Millipore Cat# 07-352, RRID:AB_310544 
 
purified IgG rabbit (PP64) EMD-Millipore Cat# PP64, RRID:AB_97852 
Virus strains 
rVACV-OVA virus a gift of 
J.W.Yewdell; NIH, 
Bethesda, MD 
N/A 
Biological Samples 
Healthy adult blood samples Fundació ACE 
(Barcelona, Spain) 
NA 
Chemicals, peptides, recombinant proteins 
OVA(323–339) peptide CNB Peptide facility N/A 
Sphingomyelinase (Bacillus cereus) Sigma-Aldrich Cat# S7651 
TAK-779 Sigma-Aldrich Cat# SML0911 
AMD-3100 Sigma-Aldrich Cat# 239820 
poly-L-lysine Sigma-Aldrich Cat# P4707 
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Ceramide (bovine spinal cord) Sigma-Aldrich Cat# 22244 
Protein A-Gold Sigma Aldrich Cat# P6730 
Streptavidin-agarose Sigma Aldrich Cat# S1638 
Ceramide from bovine spinal cord Sigma Aldrich Cat# 22244 
NIP-OVA Biosearch 
Technologies 
Cat# N-5041 
NIP-KLH Biosearch 
Technologies 
Cat# N-5042 
Aluminium hydroxide gel InvivoGen Cat# vac-alu-250 
Streptavidin APC Thermo Fisher 
Scientific 
Cat# 17-4317-82 
Streptavidin PerCP-Cy5 Thermo Fisher 
Scientific 
Cat# 45-4317-82; RRID: AB_10311495 
Dynabeads™ M-450 Tosylactivated Thermo Fisher 
Scientific 
Cat# 14013 
Proteinase K Thermo Fisher 
Scientific 
Cat# 25530049 
Streptavidin BV786 BD Bioscience Cat# 563858 
Recombinant murine CCL4 PeproTech Cat# 250-32 
Recombinant murine IL-2 PeproTech Cat# 212-12 
Recombinant murine IL-15 PeproTech Cat# 210-15 
Recombinant human IL-2 PeproTech Cat# AF-200-02 
LIVE/DEAD™ Fixable Near-IR Dead 
Cell Stain Kit 
Molecular Probes 
 
Cat# 10154363 
 
DAPI Fluoromount-G Southern Biotech Cat# 0100-20 
Thymidine, [Methyl-3H] Pelkin Elmer Cat# NET027W001MC 
SureBeads™ Protein G Magnetic Beads Bio Rad Cat# 1614023 
 
LipoD293™ In Vitro DNA Transfection 
Reagent 
SignaGen 
Laboratories 
Cat# SL100668 
Cholesterol  Avanti Polar Lipids Cat#700100 
Soybean L-α-phosphatidylcholine Avanti Polar Lipids Cat#840054C 
Egg Sphingomyelin Avanti Polar Lipids Cat#860061C 
C12 Ceramide (d18:1/12:0) Avanti Polar Lipids Cat# 860512 
C16 Ceramide (d18:1/16:0) Avanti Polar Lipids Cat# 860516 
C18 Ceramide (d18:1/18:0) Avanti Polar Lipids Cat# 860518 
C24 Ceramide (d18:1/24:0) Avanti Polar Lipids Cat# 860524 
C24:1 Ceramide (d18:1/24:1(15Z)) Avanti Polar Lipids Cat# 860525 
C16 Dihydroceramide (d18:0/16:0) Avanti Polar Lipids Cat# 860634 
C18 Dihydroceramide (d18:0/18:0) Avanti Polar Lipids Cat# 860627 
C24 Dihydroceramide (d18:0/24:0) Avanti Polar Lipids Cat# 860628 
C24:1 Dihydroceramide 
(d18:0/24:1(15Z)) 
Avanti Polar Lipids Cat# 860629 
12:0 SM (d18:1/12:0) Avanti Polar Lipids Cat# 860583 
16:0 SM (d18:1/16:0) Avanti Polar Lipids Cat# 860584 
18:0 SM (d18:1/18:0) Avanti Polar Lipids Cat# 860586 
24:0 SM Avanti Polar Lipids Cat# 860592 
24:1 SM Avanti Polar Lipids Cat# 860593 
C12 Glucosyl(β) Ceramide (d18:1/12:0) Avanti Polar Lipids Cat# 860543 
C17 sphinganine (d17:0) Avanti Polar Lipids Cat# 860654 
C17 sphinganine-1-phosphate (d17:0) Avanti Polar Lipids Cat# 860655 
Chloroform JT Baker Cat# 15588534  
Water for LC-MS JT Baker Cat# 15568664 
Methanol for LC-MS Fisher Chemical Cat# 15611630 
Ammonium formate for LC-MS Fisher Chemical Cat# 11377490  
Formic Acid for LC-MS Fluka Cat# 15671400 
Critical commercial assays 
ELISA MAX™ Deluxe Set Mouse IL-2 BioLegend Cat# 431004 
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Mouse Memory T cell CD4+/CD62L-
/CD44hi Column Kit  
R&D Systems Cat# MCD45 
Dynabeads™ Untouched™ Mouse CD4 
Cells Kit 
ThermoFisher Cat# 11415D 
Amplex™ Red Cholesterol Assay Kit ThermoFisher Cat# A12216 
EasySep™ Human CD4+ T Cell 
Enrichment Kit 
StemCell Cat# 19052 
 
SBA Clonotyping System-HRP SouthernBiotech Cat# 5300-05 
RNeasy Mini Kit QIAGEN Cat# 74104 
EZ-ChIP™ Millipore Cat# 17-371 
Experimental models: Cell lines 
HEK-293 T ATCC Cat# CRL-3216, RRID:CVCL_0063 
2B4 T cell hybridoma J. Ashwell, 
Bethesda  
RRID:CVCL_4Z38 
M.mζ-SBP (Swamy and 
Schamel, 2009) 
N/A 
Experimental models: Organisms 
B6.129P2-Ccr5tm1Kuz (CCR5-/-) The Jackson 
Laboratory 
Cat# JAX:005427, 
RRID:IMSR_JAX:005427 
C57BL/6J The Jackson 
Laboratory 
Cat# JAX:000664, 
RRID:IMSR_JAX:000664 
B6.Cg-Tg(TcraTcrb)425Cbn/J  
(OT-II) 
The Jackson 
Laboratory 
Cat# JAX:004194, 
RRID:IMSR_JAX:004194) 
OT-II-CCR5-/- (González-Martín et 
al., 2011) 
N/A 
B6.SJL-Ptprca Pepcb/Boy The Jackson 
Laboratory 
Cat# JAX:002014, 
RRID:IMSR_JAX:002014 
CD3ε-/- (DeJarnette et al., 
1998) 
N/A 
Oligonucleotides 
Primers for qRT-PCR, see Table S1  N/A 
Software and Algorithms 
Bayesian JAGS code  Provided as supplementary material  
FlowJo v10 Tree Star RRID:SCR_008520 
GraphPad Prism v6 & v7 GraphPad  RRID:SCR_002798 
NIH Image J NIH Image RRID:SCR_003073 
UCSC Genome browser University of 
California Santa Cruz 
RRID:SCR_005780 
GTRD v17.04 Gene Transcription 
Regulation Database 
http://gtrd17-04.biouml.org/ 
Venny 2.1 BioinfoGP, 
CNB/CSIC 
RRID:SCR_016561 
Adobe Photoshop CS5 Adobe Software RRID:SCR_014199 
Adobe Illustrator CS5 Adobe Software RRID:SCR_010279 
Others 
Brefeldin A Sigma-Aldrich Cat# B7651 
IntraPep Permeabilization reagent Beckman Coulter Cat# A07803 
GIPZ lentiviral mouse CerS2 shRNA 
(clones V3LMM_454307, 
V3LMM_454309, V3LMM_454311) 
Dharmacon Cat# RMM4532-EG76893 
 
Bio-Beads™ SM-2 Resin BioRad Cat# 1523920 
Acquity C8 UPLC column Waters Cat# 186002878 
 
 
Appendix Table S3. List of primers used for RT-qPCR analyses 
Gene 
Symbol 
Primer (5’ – 3’) 
Forward                                                      Reverse 
mCerS2 GGCGCTAGAAGTGGGAAAC TCGAATGACGAGAAAGAGCA 
mCerS3 GCTACACCTCTAGCAAATGCAC ATCTTTCAACCTGGCGCTCT 
mCerS4 AGATAAAGCCCAACCCGGTG GTCTCCTGAACCAGCGTTGA 
mCerS5 CCAATGCTGGTTTCGCCATC AGAACCAAGGCATCGACCAG 
mCerS6 GGAGCTGTCATTTTATTGGTCTTT GGAACATAATGCCGAAGTCC 
mASAH1 TGAAGATGGTGGATCAAAAGC ACATCTGCAATTCCCCTCA 
mACER2 GTGTGGCATATTCTCATCTG TAAGGGACACCAATAAAAGC 
mACER3 TGACCTTGTTCGTCGCTGAG AGCAATGTACCGCTTCTCCA 
mSMPD1 TGGTTCTGGCTCTGTTTGACTCCA TCAGCTGATCTTGGCGAGACTGTT 
mSMPD2 GGTGCTCAACGCCTATGTG CGTCTGCCTTCTTGGATGTG 
mSMPD3 AGAAACCCGGTCCTCGTACT CCTGACCAGTGCCATTCTTT 
mSMPD4 GCCAACGACCTGGACGAGATC GCGAGTGTGAACTGCCTGAG 
CCR5 TCCGTTCCCCCTACAAGAGA TTGGCAGGGTGCTGACATAC 
mTcra CCAGACTGGCAGCAAGAAGAAAAT TCACAGCTCCCCACCATATTC 
mTcrb GTGCTGTGAAGGATGGCAACT CGGCAGGGTCAGGGTTCT 
mCD3d TGTGCAAGTCCATTACCGAAT AAAGCAGTAGACGCCCAAAG 
mCD3g GAGAAGCAAAGAGACTGACATGG TTATTTGTCTGGGCTACAGTGC 
mCD3e AACACTTTCTGGGGCATCCT ATGTTCTCGGCATCGTCCT 
mCD3z GCACGATGGCCTTTACCA CAAGTGACATCAGCAGGTGAA 
mGATA-1 TGCTCTCTTCTTGAGGCATAGATT CCAGCCCTGCTGTTTAGAGTC 
mHISTH3 GCTAAGCTTAACTCTCCCGGT AAGCGCCCAGCAGCC 
hCerS2 GACGGAGTACACGGAGCAG CGTTCCCACCAGAAGTAATCA 
hCerS4 TGGTGCTGCTGTTACACGAT TGATACTGCATGTAGTTGACCATC 
hCerS5 CACATCCTCTCGGTGTTCC CAGGGTTTGGCAATAAATCG 
hCerS6 CGACTGGGTATATTTCCTCTCTG GGAAGGGTAAGGTCCAACG 
hASAH1 CACGCTGATTGGGTGTGTA CGATGTTCAGCTTGTATTTCTTGA 
hACER2 TGTGGTTCCCCAGAAGGTAT ACGTCGTAACCGCAGACAG 
hACER3 CCTGAGATATAGGCCAAAAGTGA GCCAGGTCTATGGTAGGTGCT 
hSMPD1 TGGCTCTATGAAGCGATGG TGGGGAAAGAGCATAGAACC 
hSMPD3 TGGTACCCAAGAACTGCTACG AAAACCCAGAAACTGCCTTG 
18S rRNA GAGAAACGGCTACCACATCC GGGTCGGGAGTGGGTAAT 
 
 
 
 
Bayesian code for the R-language 
 
 
 
 
# require(rjags) 
# The array "p" contains 4 different cluster size counts from different 
experiments for the same mouse and time 
cluster.jags.multix4 <- function(p) { 
  p1 <- p[1,] 
  p2 <- p[2,] 
  p3 <- p[3,] 
  p4 <- p[4,] 
  data <- 
list(p1=p1,p2=p2,p3=p3,p4=p4,m=length(p1),N1=sum(p1),N2=sum(p2),N3=sum(p3),N4=su
m(p4))  
   
  modelstring=" 
  model { 
  for(n in 1:(m-1)) { 
     pi1[n] <- b1^(n-1)*(1-b1) # Analytical distribution described in the main 
text 
     pi2[n] <- b2^(n-1)*(1-b2) 
     pi3[n] <- b3^(n-1)*(1-b3) 
     pi4[n] <- b4^(n-1)*(1-b4) 
  }    
  pi1[m] <- b1^(m-1)  # Analytical distribution described in the main text 
  pi2[m] <- b2^(m-1) 
  pi3[m] <- b3^(m-1) 
  pi4[m] <- b4^(m-1) 
 
  p1 ~ dmulti(pi1,N1) # The counts are given by a multinomial distribution with 
probabilities "pi" 
  p2 ~ dmulti(pi2,N2) 
  p3 ~ dmulti(pi3,N3) 
  p4 ~ dmulti(pi4,N4) 
 
  b1 ~ dbeta(A,B) # Priors for the parameters b1.  
  b2 ~ dbeta(A,B) 
  b3 ~ dbeta(A,B) 
  b4 ~ dbeta(A,B) 
  A ~ dunif(0,1000) # Hyperpriors for A and B (0 = uniform distribution, 
Infinity=peaked distribution) 
  B ~ dunif(0,1000) 
  }" 
   
  model=jags.model(textConnection(modelstring), data=data,n.chains = 3) # Create 
jags model 
  update(model,n.iter=10000) # Burning phase of the MCMC model 
  output=coda.samples(model=model,variable.names=c("A","B","b1","b2","b3","b4"), 
n.iter=15000, thin=1) # Sample data 
  print(summary(output)) # Print estimated parameters 
  return(output) # return matrix of results for post-processing 
} 
